Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis

Modified premedication scheme consisting of 1 g/day of IV methylprednisolone throughout all 5 days of alemtuzumab treatment may reduce overall IARs. Intravenous administration of antipyretics may work better than oral administration.